WAL0921
/ Walden Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
March 25, 2026
Study of WAL0921 in Patients With Glomerular Kidney Diseases
(clinicaltrials.gov)
- P2 | N=96 | Recruiting | Sponsor: Walden Biosciences | Trial completion date: Mar 2026 ➔ Jun 2027 | Trial primary completion date: Oct 2025 ➔ Mar 2027
Trial completion date • Trial primary completion date • Focal Segmental Glomerulosclerosis • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease
July 12, 2024
Study of WAL0921 in Patients With Glomerular Kidney Diseases
(clinicaltrials.gov)
- P2 | N=96 | Recruiting | Sponsor: Walden Biosciences | Not yet recruiting ➔ Recruiting
Enrollment open • Focal Segmental Glomerulosclerosis • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease
June 20, 2024
Study of WAL0921 in Patients With Glomerular Kidney Diseases
(clinicaltrials.gov)
- P2 | N=96 | Not yet recruiting | Sponsor: Walden Biosciences
New P2 trial • Focal Segmental Glomerulosclerosis • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease
April 10, 2024
Single Ascending Dose Study of WAL0921 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=40 | Completed | Sponsor: Walden Biosciences | Recruiting ➔ Completed
Trial completion
June 06, 2023
Single, Ascending Dose Study of WAL0921 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Walden Biosciences
New P1 trial
1 to 5
Of
5
Go to page
1